IZOKIBEP PHASE 2B/3 HIDRADENITIS SUPPURATIVA DATA PRESENTED AT THE 2023 AMERICAN ACADEMY OF DERMATOLOGY ANNUAL MEETING
• At 12 weeks, 57% of patients achieved HiSCR75, 38% achieved HiSCR90 and 33% achieved HiSCR100.• Safety results were consistent with previous trials of izokibep, with no increased risk of infections. Solna, Sweden, March 18, 2023. Affibody today announced that topline 12-week data from treatment with izokibep in the open label part (Part A) of a Phase 2b/3 trial in patients with moderate-to-severe Hidradenitis Suppurativa (HS) will be presented in a Late-Breaking plenary session at the American Academy of Dermatology (AAD) Annual Meeting in New Orleans, USA.The data from the open